Michael McShea, RPH
Advertisement
Articles by Michael McShea, RPH
Pharmacists must be experts on follow-on biologics (FOBs), including biosimilars, so they can provide education to health professionals about safe prescribing and use, which ultimately affects patient care.
Pharmacists need to be experts on follow-on biologics, including biosimilars, so they can provide education to health professionals about safe prescribing and use.
Health care practitioners need to prepare for myriad questions regarding biosimilars and follow-on biologic drugs as they enter the market.
Advertisement
Latest Updated Articles
Biosimilars and Follow-on Biologics: A Pharmacist OpportunityPublished: November 17th 2016 | Updated:
Biosimilars and Follow-on BiologicsPublished: September 28th 2017 | Updated:
Embracing Concentrated Insulins: With a Focus On Humulin R U-500Published: July 21st 2018 | Updated:
Biosimilars and Follow-on Biologics: A Pharmacist OpportunityPublished: October 12th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
3
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
4
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
5
